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LYMPHOID tumours originating in the thymus can be induced in a high inci-
dence in Swiss mice when they are given a single injection of 7,12-dimethylbenz(a)-
anthracene (DMBA) shortly after birth (Pietra, Spencer and Shubik, 1959).
Newborn animals are more susceptible to this leukaemogenic effect ofDMBA than
animals 2-4 months old (Toth, Rappaport and Shubik, 1963). It has been also
demonstrated that there exists a strain difference in tumorigenic response to
DMBA (Kelly and O'Gara, 1961; Roe, Rawson and Salaman, 1961).
Woolley and Peters (1953), Upton and Furth (1954), Levinthal and Eaton
(1966) and Liebelt and Liebelt (1962) have reported that death either from
spontaneous AKR leukaemia or from virus induced leukaemia is delayed or
inhibited by monthly or continued courses of cortisone treatment. Thymus
involution induced by the lympholytic action of cortisone is regarded as being a
cause of the delay of leukaemia development. Likewise, administered cortisone
proved to be inhibitory to the occurrence of both chemical- and x-ray-induced
leukaemia (Liebelt and Liebelt, 1962; Kaplan, Brown and Marder, 1951). Neo-
natal injection of glucocorticoids induces a wasting syndrome in mice and rats
similar to that observed in runt disease and in the post-thymectomy syndrome
(Schlesinger and Mark, 1964; Fachet et al., 1966). The hormone-treated animals
show markedreductions intheweights ofthethymus andspleen, accompanied by a
profound depletion of small lymphocytes and by impairment of the immuno-
logical response (Schapiro and Huppert, 1966).
The aim of the present investigation was to examine the effect of neonatal
administration of cortisone acetate on induction of lymphoma by the single
application ofDMBA.
MATERIALS AND METHODS
Inbred strains of C57BI/6J and A/Jax and non-inbred albino Swiss mice,
raised in our laboratory, were used. Incidence of spontaneous leukaemia at 26
weeks of age is less than 2% in all the strains used. In the experiment with
Swiss mice, newborns less than 24 hours after birth received a single intraperitoneal
injection of cortisone acetate, suspended in saline solution, followed by a single
subcutaneous injection of DMBA, suspended in 1-0% aqueous gelatine solution,
on the 3rd day of life. In another group of mice, the treatment sequence was
reversed; DMBA injection was given within 24 hours after birth and cortisone
was injected on the 3rd day oflife. In a third group cortisone was injected withinLEUKAEMOGENESIS IN MICE
24 hours after birth and then DMBA was given 3 hours later. In the other groups
of mice, cortisone was given within 24 hours after birth and DMBA was given on
the 2nd, 5th, or 10th day of life. Control mice received DMBA treatment alone
within 24 hours after birth, on the 2nd, 3rd, 5th, or 10th day of life. In the
experiments with C57BI and A/Jax mice, cortisone treatment was given within
24 hours after birth, followed by DMBA injection 3 days later. Controls were
injected with DMBA alone either within 24 hours after birth or on the 3rd day.
The amount of DMBA given was 60 ,ug. (0.03 ml. of the vehicle) in newborns
and 100 ltg. (0.05 ml.) in 2-10-day-old mice. The amount of cortisone acetate
given was 0-2 mg. (0.03 ml. of the vehicle) and 0 33 mg. (0.05 ml.) in newborn and
in 3-day-old mice, respectively. Since newborn C57B1 mice were sensitive to
neonatal exposure to cortisone, producing a fatal cachectic condition which was
similar to the wasting syndrome after neonatal thymectomy, the amount was
reduced to 0 15 mg. in some instances.
Animals were weaned at 3-4 weeks and caged in groups of 3-6 according to
sex, fed a commercial compressed diet and water ad libitum. They were periodi-
cally checked for the development oflymphoma. Animals were killed when they
showed severe clinical signs of lymphoma or when it seemed that death was
imminent. The 26-week survivors were also killed irrespective of evidence of
leukaemia. All the animals were autopsied, and lymphomas as well as other
tumours, particularly lung adenomas, were recorded. The tissues were examined
histologically.
RESULTS
Results obtained in Swiss mice, the most susceptible strain to DMBA leukae-
mogenesis, are summarized in Table I and Fig. 1. Lymphomas appeared in
TABLE L.-Effect of Cortisone Injection on DMBA Leukaemogenesis in Swiss Mice
Mice with leukaemia
Treatment No. oft
A_ mice Mean latent period
NB* 3 days* used No. (%) (days)
DMBAt - . 75 . 63 84-0 113.6 (120)§
- DMBA . 24 . 21 87 5 103-3 (104)
Cortisonell DMBA . 33 . 29 87.9 84-6 ( 86)
DMBA CortisoneT . 21 . 12 57-1 117-2 (147)
DMBA± - . 28 . 12 42-8 109*4(-)
Cortisone
* NB: within 24 hours after birth, 3 days: on the 3rd day of life.
t DMBA 60 ,ug. at NB.
$ DMBA 100 ,zg. on the 3rd day of life.
II Cortisone 0-2 mg. at NB,
T Cortisone 0 33 mg. on the 3rd day of life.
§ Age of mice at 50% cumulative incidence of leukaemia.
84.0%, 63 of 75 mice treated with DMBA as newborns, and in 87.5%, 21 of 24
mice treated on the 3rd day, the incidence being at the same level in the 2 groups.
The mean latent period was 113-6 days in the former group and 103-3 days in the
latter. In the group that received pretreatment with cortisone the lymphoma
incidence was 87-9%, 29 of 33 mice, no increase in the incidence being attained
compared with that in the groups which received DMBA exposure alone. How-
ever, cortisone pretreatment reduced the mean latent period by 20-30 days,
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FiG. 1.-Effect of i.p. injection of cortisone acetate on DMBA-leukaemia incidence in Swiss
mice. (0 O) s.c. injected with 60 pg. of DMBA within 24 hours after birth or s.c.
injected with 100 pg. ofDMBA on the 3rd day oflife; (0 0) injectedwith 0-2 mg. ofcor-
tisone acetate within 24 hours after birth andfollowed by s.c. injection of 100 pg. ofDMBAon
the 3rd day oflife; ( x x ) s.c. injected with 60 pg. of DMBA within 24 hours after birth
and followed by an injection of0-33 mg. ofcortisone acetate on the 3rd day oflife; (U * *)
injected with 0-2 mg. of cortisone acetate and 60 pg. of DMBA within 24 hours after birth.
compared with that in the former 2 groups. In contrast, an apparent inhibition
of lymphoma incidence was observed in the group where the treatment sequence
was reversed; that is, DMBA exposure followed by cortisone treatment. Only
12 of 21 mice, 57-1%, developed leukaemia with a mean latent period of 117-2
days. This was also the case in the group where both treatments were given
simultaneously within 24 hours after birth. The incidence was 42.8%, 12 of 28
mice, and the mean latent period was 109-4 days. As seen in Table II, enhance-
ment of leukaemia development was observed in the groups that were given
cortisone treatment 2-5 days before DMBA exposure.
TABLE II.-Effect on Leukaemogenesis ofInterval Between Cortisone
Injection and DMBA Treatment
Mice with leukaemia
Cortisone No. of
injection* DMBA mice Mean latent period
(within 24 hours) treatmentt used No. (%) (days)
+ . 2 days . 11 . 9 81-8 87-6
- . , 11 . 7 63- 6 108-2
+ . 5 days . 15 . 12 80-0 91-3
- -. ,, . 14 . 9 64-3 109-4
+ 10 days . 10 . 5 50-0 122-3
- . ,, . 15 . 7 38.9 135-7
* Cortisone 0-2 mg.
t DMBA 100 pg.
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TABLE III.-Enhancement ofDMBA Leulkaemogenesis by Cortisone
Pretreatment at Neon,atal Age in C57B1/6 and AIJax Mice
C(
tr
Strain
C57Bl/6
A/Jax
ortisone
eatment
No. of
mice
(mg.) used No. (%)
-* . 41 . 10 24 4
15-0 2t . 27 . 20 74-1
-* . 10 . 3 30 0
0 2t . 7 . 5 71.4
Mice with leukaemia
Mean latent period
(days)
148-0
116*4
170 6
158-6
* DMBA injection (s.c.) was given at birth or on the 3rd day of life.
t Cortisone injection (i.p.) was given within 24 hours after birth and DMBA injection
(s.c.) was given on the 3rd day oflife.
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FIG. 2.-Effect ofi.p. injection ofcortisone acetate on DMBA-leukaemia incidence in C57B1/6J
(solid line) and A/Jax (dotted line) strains of mice. (0) s.c. injected either with 60,g.
(within 24 hours after birth) or with 100 jug. (on the 3rd day oflife) ofDMBA. (0) injected
with 0. 15-0-2 mg. of cortisone acetate within 24 hours after birth and followed by s.c.
injection of 100 ,ug. of DMBA on the 3rd day of life.
The results in the C57B1 and A/Jax strains of mice are shown in Table III
and Fig. 2. Since there was no significant difference in leukaemogenic response
between the 3rd day-treated and the newborn-treated mice with DMBA, pooled
data are given in these illustrations. The lymphoma incidence in the DMBA-
treated group was 24.4% and 30.0% in C57B1 and A/Jax mice, respectively. The
incidence in the cortisone-DMBA-treated group was 74-1% and 71.4% in C57B1
and A/Jax mice respectively, with a reduction in the mean latent period by
10-30 days. Thus, it was apparent that cortisone administration before DMBA
exposure showed an enhancing effect on leukaemogenesis in both strains. The
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leukaemogenic response to DMBA of the cortisone pretreated C57B1 and A/Jax
mice could be ranked at almost the same level as that of susceptible Swiss mice.
It was of interest that synergism was even more evident here than in the experi-
ment with Swiss mice because of the low level of susceptibility of C57B1 and
A/Jax strains.
In all the experimental groups no sex difference in leukaemia development
was observed and the lymphomas were typical thymic lymphomas, localized or
generalized, especially showing lymphatic leukaemia or lymphosarcoma and
identical with those arising in the most susceptible Swiss mice after a single
neonatal injection of DMBA. The number of sarcomas arising at the site of
DMBA injection was negligible, since only three mice of the C57B1 strain among
all mice used developed subcutaneous fibrosarcoma. Other tumours most often
induced by neonatal injection of DMBA were multiple lung adenomatosis. The
combined treatment with cortisone and DMBA did not affect the incidence or
the time interval between DMBA injection and the onset of lung adenomatosis.
DISCUSSION
The results reported here indicated that cortisone acetate, when given before
DMBA exposure, potentiated the leukaemogenic activity of DMBA in all the
strains of mice examined. Considerable evidence has been accumulated in
support ofthe hypothesis that depression ofthe immune response may play a role
in tumour development. Although it has been demonstrated that neonatal
injection of glucocorticoid impairs the immunological response for at least 60-70
days after treatment (Schapiro and Huppert, 1966), it seems unlikely that
the leukaemogenic enhancement in the present experiments is mediated only by
immunological depression of hosts induced by cortisone injection. If this is true,
one could not explain the inhibitory effect on leukaemogenesis of cortisone given
simultaneously with or after DMBA administration. Upton and Furth (1954)
reported previously that cortisone given before irradiation increased and after
irradiation decreased the incidence ofradiation-induced lymphomas in young male
mice of the RF strain. The precise mechanism whereby DMBA-lymphoma
formation is inhibited by simultaneous treatment and post-treatment with
cortisone is not clear, although it is probable that potentially-leukaemic cells
responding to DMBA exposure are eliminated by the lympholytic action of
cortisone. An explanation of the potentiation induced by pretreatment with
cortisone may be provided by the fact that cortisone causes severe thymic involu-
tion which is followed by rapid regeneration with a concomitant repopulation by
immature lymphocytes (Ito and Hoshino, 1962). It has been suggested that
the population of immature lymphocytes in the thymus may be correlated with
susceptibility to viral and x-ray leukaemogenesis (Axelrad and van der Gaag,
1962; Kaplan, 1961). Studies along this line are under progress in our laboratory.
Toth (1965) and Haran-Ghera (1967) reported successful recovery of a filter-
able agent, a leukaemia virus, from DMBA-induced lymphomas. If this could be
extended to our system, it might also be possible that pretreatment with cortisone
might provide the proper tissue environment in which a leukaemogenic virus
naturally harboured in many strains of mice, that normally remains in a silent
state, can achieve its leukaemogenic activity more efficiently. In this connection,
it is noteworthy that leukaemia development by PassageA virus (Gross) in hybrids
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of AKR x A/Jax constitution is also enhanced by cortisone injection at the
neonatal stage (unpublished data).
SUMMARY
Subcutaneous injection of 7,12-dimethylbenz(a)anthracene (DMBA) in 1.0%
gelatine solution, in newborns (60 jug.) and 3-day-old mice (100 ,ug.) of Swiss,
C57B1/6 and A/Jax strains resulted in thymic lymphoma development with the
incidence of approximately 85%, 24% and 30%, respectively, within 26 weeks
after the treatment, a strain difference in susceptibility being observed. A
neonatalintraperitoneal singleinjectionof0-15-0 2 mg. ofcortisoneacetatefollowed
by a subcutaneous injection of 100 jug. of DMBA on the 2nd, 5th, or 10th day of
life, significantly increased the lymphoma incidence and shortened the mean
latent period in all the strains used. This indicates that cortisone treatment
preceding DMBA exposure has an enhancing effect on leukaemia development.
In contrast, cortisone injection given simultaneously or 3 days after DMBA
administration reduced the lymphoma incidence in Swiss mice.
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